A new EXOMIND machine costs $100,000-$200,000 from BTL Industries or authorized reps. That is the capital price for the console and the patented ExoTMS coil, before training, service, or bundle pricing. The actual transaction price is almost always below list, especially for end-of-quarter and end-of-year deals where reps have quota pressure to close. Single-device deals commonly land 10-20% under the published list price.
There is no meaningful used or refurbished EXOMIND market yet. BTL cleared the device with the FDA in 2024, so the installed base is young and early owners are not reselling units. Buyers who want a discount are negotiating on a new unit rather than shopping the secondary market. A thin used market also means trade-in valuations are speculative, so do not let a rep claw back a new-device discount on an inflated trade-in number.
For practices financing through equipment leasing companies or commercial bank loans, monthly payments at typical equipment rates (6-9% APR over 60 months) run approximately $2,030-$4,060. Financed equipment still qualifies for the Section 179 tax deduction, which can dramatically improve first-year cash flow.
Total cost of ownership (5-year)
The purchase price is most of the EXOMIND total cost of ownership. Unlike laser or RF aesthetic platforms, a TMS-style device has no disposable applicator tips or single-use consumables per treatment, so the recurring spend is dominated by the service contract rather than per-session supplies. Budget roughly $3,000-$6,000 a year for service once the warranty lapses, plus staff training, marketing to drive patient volume, and occasional software updates.
For a typical practice, five-year TCO on EXOMIND runs roughly 1.3x to 1.6x the original purchase price, lower than consumable-heavy devices because there is no per-treatment supply burden. The bigger swing factor is whether you keep the schedule full, since the fixed financing payment is the same whether the device runs two patients a day or six.
The largest hidden cost on a low-consumable platform is idle capacity, not supplies. A device that sits unused still owes its monthly payment and service contract. Always model TCO against realistic treatment volume, not the rep's best-case projection, before signing a purchase contract.
EXOMIND financing options
Most physicians finance medical devices in this price range rather than paying cash. Financing options include:
Manufacturer financing. BTL Industries typically offers in-house or partnered financing programs with rates competitive with bank equipment loans. Manufacturer financing can be combined with promotional pricing during end-of-quarter sales pushes.
Equipment leasing companies. Specialized medical equipment lessors offer fair market value (FMV) leases, $1 buyout leases, and operating leases. Lease terms typically run 36-60 months. FMV leases offer the lowest monthly payment but require a buyout decision at lease end.
Commercial bank equipment loans. Local and regional banks offer equipment loans at competitive rates, usually requiring strong practice credit and personal guarantees. Bank loans typically have lower total cost than manufacturer or third-party financing for practices with strong credit.
SBA loans. The SBA 7(a) and 504 loan programs can finance medical equipment for qualifying small practices, with longer terms (up to 10 years) and lower down payments than conventional financing.
Always compare manufacturer financing against independent equipment lenders to ensure competitive rates. Manufacturer financing rates can be inflated when bundled with promotional pricing.
Section 179 tax deduction for EXOMIND
Section 179 of the IRS Tax Code allows businesses to deduct the full purchase price of qualifying equipment in the year it's placed in service, up to an annual limit of $2,560,000 for tax years beginning in 2026 (with a phase-out starting at $4,090,000 of total equipment purchases). EXOMIND is capital medical equipment and qualifies for Section 179, well under the cap.
At a 35% effective tax rate, a practice buying a new EXOMIND can deduct approximately $35,000-$70,000 in the year of purchase, reducing the after-tax cost to roughly $65,000-$130,000. Section 179 applies to financed equipment as well, which means you can claim the full deduction in year one even if you're paying for the device over five years. This can create substantial first-year cash flow benefits.
Section 179 must be claimed on your business tax return for the year the equipment is placed in service (not just purchased). Equipment installed and operational by December 31 qualifies for that tax year. End-of-year purchases are common in medical device buying for this reason. Always consult your CPA to optimize Section 179 timing alongside bonus depreciation and other deductions.
Per-treatment economics
EXOMIND patient pricing runs about $400-$600 per session, and the standard FDA-cleared depression course is six sessions, so a full treatment plan bills roughly $3,000-$4,800. Most clinics package the course rather than billing session by session, which improves completion rates and protects revenue. EXOMIND is cash-pay; there is no established US insurance reimbursement pathway for the BTL platform yet, so model revenue on out-of-pocket pricing.
Because there are no per-treatment consumables, gross margin per session is high once the fixed costs are covered. The main variable cost is operator labor for the 25-30 minute session. The gross margin must still cover the fixed costs of capital ownership: monthly financing payments, the service contract, staffing, marketing, and rent allocation. Without consistent volume, those fixed costs are what sink the economics.
The most common mistake in projecting EXOMIND economics is over-estimating treatment volume. Physicians who model 4-6 treatments per day rarely hit those numbers in year one, especially for a 2024-cleared device that patients are still learning about. Run your projections on conservative volume (1-3 treatments per day), and validate the math before signing a purchase contract.
Resale value and trade-in
Because EXOMIND only reached the US market in 2024, there is not yet a deep secondary market to set a clean resale benchmark. TMS-style consoles from established makers typically retain roughly 50-70% of purchase price in their first few years, and EXOMIND is likely to track that range as the installed base matures. For now, resale value will depend on several factors:
Age of unit. Newer units (under 3 years) hold value better than older ones.
Software version. Devices with current software command premiums. Outdated software can drop value by 30 to 50 percent.
Applicator condition. Worn or damaged applicators reduce resale value.
Remaining warranty. Warranty transfers (where allowed by manufacturer) increase value.
Manufacturer health. Devices from financially stable manufacturers hold value better. Devices from struggling manufacturers depreciate faster.
BTL Industries typically offers trade-in credit for older devices when buying new units, though the trade-in valuation is often where manufacturers claw back the discount on the new device. Always get an independent valuation before accepting a trade-in offer.
What to negotiate with BTL Industries
Capital equipment sales reps have significant pricing flexibility that practice buyers rarely fully capture. Beyond the headline discount, the items worth negotiating include:
Extended warranty and service coverage. Push for 24-36 months instead of the standard 12, and get the post-warranty service price in writing up front.
Coil and accessory inclusions. Confirm the ExoTMS coil, positioning hardware, and any spare components are included rather than billed separately.
Training and certification. Multiple providers should be trained without additional fees.
Marketing and launch support. Co-marketing funds, patient education materials, or launch campaign support, which matter more for a 2024-cleared device patients are still learning about.
Software and licensing terms. Ask whether any indications or features are gated behind separate licensing fees that do not show up in the headline number.
Bundle pricing if you already run BTL aesthetic devices, since cross-platform deals carry the most flexibility.
End-of-quarter and end-of-year timing give you the strongest negotiating position. Bundled deals (multiple devices or multi-year service contracts) close at 20-30% below list. The mistake most physicians make is accepting the first deck without pushing back on any of these items.
Frequently Asked Questions
How much does an EXOMIND machine cost?
A new EXOMIND machine costs $100,000-$200,000 from BTL Industries or authorized reps. The used market is thin because the device was only FDA-cleared in 2024. Patient-facing pricing runs $400-$600 per session, or roughly $3,000-$4,800 for the standard six-session depression course. There are no per-treatment consumables; the main recurring cost is the service contract, roughly $3,000-$6,000 a year after warranty.
Can I finance EXOMIND?
Yes. Most physicians finance medical devices in this price range through equipment leasing companies, manufacturer financing programs, or commercial bank equipment loans. Financed at typical equipment loan rates (6-9% APR over 60 months), monthly payments on a new EXOMIND run approximately $2,030-$4,060. Section 179 tax deductions apply even on financed equipment.
What's the total cost of ownership for EXOMIND?
Five-year total cost of ownership includes the purchase price ($100,000-$200,000), the service contract (roughly $3,000-$6,000 a year after warranty), and incidental costs (training, marketing, software updates). EXOMIND has no per-treatment consumables, so TCO runs lower than consumable-heavy aesthetic devices, roughly 1.3x to 1.6x the original purchase price for a typical practice.
Should I buy EXOMIND new or used?
For EXOMIND the practical answer is new. New units ($100,000-$200,000) include warranty, current software, and training. The used market is thin because BTL only cleared the device in 2024, so there is little clean secondary inventory and resale benchmarks are not yet established. Buyers who want a discount are better off negotiating on a new unit than waiting for a used one to surface.
Does Section 179 apply to EXOMIND?
Yes. EXOMIND qualifies for Section 179 tax deduction. At a 35% effective tax rate, a practice buying a new unit can deduct approximately $35,000-$70,000 in the year of purchase, reducing the after-tax cost to roughly $65,000-$130,000. Consult your CPA to optimize Section 179 with bonus depreciation and other deductions.
What's the per-treatment economics on EXOMIND?
Patients pay $400-$600 per session and roughly $3,000-$4,800 for the standard six-session course. EXOMIND has no per-treatment consumables, so the main variable cost is operator labor for the 25-30 minute session, which keeps gross margin per session high once fixed costs are covered. The economics live or die on schedule fill, since the financing payment and service contract are owed regardless of volume. EXOMIND is cash-pay with no established US insurance pathway yet.
What's the resale value of EXOMIND?
There is not yet a deep used EXOMIND market to set a clean resale benchmark, since the device only reached the US in 2024. TMS-style consoles from established makers typically retain roughly 50-70% of purchase price in their early years, and EXOMIND is likely to track that range as its installed base grows. Resale value will depend on age, software version, remaining warranty, and overall platform demand.
How can I negotiate EXOMIND pricing with BTL Industries?
Capital equipment sales reps have significant pricing flexibility. Most deals close 10-20% below list price for single-device purchases and 20-30% below list for multi-device bundles. End-of-quarter and end-of-year timing gives you the strongest negotiating position. Always negotiate applicator inclusions, consumable starter packages, extended warranty coverage, training fees, and trade-in credit on existing devices. Bundled deals can reduce effective capital cost by 25-35% versus the initial quote.